Company / Cash & Equivalents
Armata Pharmaceuticals, Inc. Cash & Equivalents History
FY2014-FY2014 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$6.6M
FY2014
5-year range
$6.6M / $6.6M
FY2014-FY2014
Trend
-
vs FY2013
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$7M in FY2014.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -12.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2014 | $6.6M | - |
As of FY2014 · SEC 10-K · Updated Jun 21, 2026